Okay, let's tackle this question. The user wants a detailed explanation for a multiple-choice question about a tissue schizontocide that prevents relapse of vivax malaria. The correct answer is supposed to be provided, but the options are empty. Wait, the user probably forgot to fill in the options. But since the correct answer is given as an empty string, maybe they expect me to know the standard answer here.

First, I need to recall the drugs used in malaria and their mechanisms. Vivax malaria is caused by Plasmodium vivax. The key here is the term "tissue schizontocide." Schizonticides kill the schizonts, which are the forms of the parasite that multiply in the liver (exo-erythrocytic stage) and in the blood (erythrocytic stage). Tissue schizontocides target the liver stage, preventing the release of merozoites into the bloodstream, which would cause a relapse.

The drugs that act on the liver stage are called primaquine and tafenoquine. These are known as terminal schizontocides because they eliminate the dormant hypnozoites in the liver, which are responsible for relapses in vivax and ovale malaria. So the correct answer should be either primaquine or tafenoquine.

Now, the options aren't listed, but common distractors might include chloroquine, which is a blood schizonticide but doesn't act on the liver stage. Another might be mefloquine, which is used for prophylaxis but not for eliminating hypnozoites. Artemisinin derivatives are also blood schizontocides. So the incorrect options would be drugs that don't target the tissue schizonts.

The clinical pearl here is that only primaquine and tafenoquine can prevent relapses by targeting hypnozoites. Students often confuse this with drugs that just treat the acute infection, like chloroquine or artemisinin. Also, G6PD deficiency is a contraindication for primaquine because of the risk of hemolysis, so that's an important point to mention in the clinical pearl.

Putting it all together, the core concept is about eliminating hypnozoites in the liver to prevent relapse. The correct answer is the drug that does that, which is primaquine or tafenoquine. The wrong options are other antimalarials that don't target the liver stage. The clinical pearl emphasizes the importance of these drugs in preventing relapse and the need to check for G6PD status.

**Core Concept**
The question tests knowledge of antimalarial drugs targeting hepatic hypnozoites in *Plasmodium vivax* malaria. Tissue schizontocides eliminate dormant liver-stage parasites (hypnozoites), preventing relapses. Primaquine and tafenoquine are the only drugs with this activity.

**Why the Correct Answer is Right**
Primaquine irreversibly oxidizes hypnozoites in the liver, destroying them and preventing their release into the bloodstream. This eradicates the exo-erythrocytic reservoir of *P. vivax*, which is the source of relapses. Tafenoquine acts similarly but has a longer half-life, allowing once-weekly dosing. Both drugs are termed "radical curatives" for their role in preventing relapses.

**Why Each Wrong Option

✓ Correct Answer: B. Primaquine